SCHEDULE: Bellevue Group Discloses 5.4% Stake in Celldex Therapeutics

Bellevue Group AG and its subsidiary Bellevue Asset Management AG have reported a 5.4% beneficial ownership stake in Celldex Therapeutics, Inc. common stock.

Summary

• Bellevue Group AG and its wholly-owned subsidiary, Bellevue Asset Management AG, have jointly filed a Schedule 13G.
• They beneficially own 3,617,669 shares of Celldex Therapeutics, Inc. Common Stock.
• This represents 5.4% of the class, calculated based on 66,449,471 shares deemed outstanding.
• Both entities hold shared voting power and shared dispositive power over all 3,617,669 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: Neutral. This is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment about the issuer's performance or prospects. It simply indicates an institutional investor's position.

Future Outlook

N/A. This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting entities regarding the issuer's future performance.

Industry Context

This filing indicates a significant institutional investment in Celldex Therapeutics, a biotechnology company. Such disclosures are common as investment firms build or adjust their positions in publicly traded companies, particularly within the often volatile and research-intensive biotech sector. A 5.4% stake suggests a notable, but not controlling, interest by Bellevue Group AG.

Stakeholder Impact

• Shareholders of Celldex Therapeutics will note a significant institutional investor, Bellevue Group AG, has taken a 5.4% stake, potentially signaling confidence in the company's long-term prospects or strategic direction.

Key Dates

Keywords

Celldex Therapeutics, Bellevue Group AG, Bellevue Asset Management AG, CDLX, Schedule 13G, Beneficial Ownership, Institutional Investor, Biotechnology, Pharmaceuticals